Ensign Peak Advisors Inc Decreases Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Ensign Peak Advisors Inc lowered its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 20.4% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 84,950 shares of the medical research company's stock after selling 21,778 shares during the period. Ensign Peak Advisors Inc's holdings in IQVIA were worth $16,694,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of IQV. Smith Group Asset Management LLC bought a new stake in shares of IQVIA in the 4th quarter valued at about $1,616,000. Hickory Asset Management Inc. bought a new stake in shares of IQVIA in the 4th quarter valued at about $941,000. Fifth Third Bancorp grew its position in shares of IQVIA by 13.0% in the 4th quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company's stock valued at $2,590,000 after buying an additional 1,521 shares during the last quarter. Graphene Investments SAS grew its position in shares of IQVIA by 22.0% in the 4th quarter. Graphene Investments SAS now owns 15,000 shares of the medical research company's stock valued at $2,948,000 after buying an additional 2,700 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its position in shares of IQVIA by 46.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company's stock valued at $437,378,000 after buying an additional 583,396 shares during the last quarter. Institutional investors own 89.62% of the company's stock.

Analyst Ratings Changes

IQV has been the topic of a number of analyst reports. Mizuho reduced their price target on IQVIA from $210.00 to $190.00 and set an "outperform" rating on the stock in a research report on Thursday. BTIG Research downgraded IQVIA from a "buy" rating to a "neutral" rating in a research note on Monday, February 3rd. Royal Bank of Canada reissued an "outperform" rating and issued a $270.00 price objective on shares of IQVIA in a research note on Monday, February 10th. Truist Financial decreased their price target on IQVIA from $263.00 to $216.00 and set a "buy" rating for the company in a research report on Thursday, April 10th. Finally, Hsbc Global Res lowered IQVIA from a "strong-buy" rating to a "hold" rating in a report on Friday, April 25th. Eight research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $230.76.

IQVIA Price Performance

NYSE:IQV traded up $2.23 during trading hours on Friday, hitting $142.66. 2,227,287 shares of the company's stock traded hands, compared to its average volume of 1,514,419. The firm has a market cap of $24.68 billion, a P/E ratio of 19.02, a P/E/G ratio of 1.99 and a beta of 1.34. IQVIA Holdings Inc. has a 52 week low of $135.97 and a 52 week high of $252.88. The business's fifty day simple moving average is $159.83 and its two-hundred day simple moving average is $185.86. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.63 by $0.07. IQVIA had a return on equity of 28.81% and a net margin of 8.91%. The firm had revenue of $3.83 billion during the quarter, compared to analyst estimates of $3.77 billion. During the same quarter in the previous year, the company posted $2.54 earnings per share. The company's revenue was up 2.5% compared to the same quarter last year. On average, research analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.